Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials with VP-102 CAMP-1 and CAMP-2. J of Skin [Internet]. 2021 Nov. 5 [cited 2025 Oct. 13];5(6):s92. Available from: https://skin.dermsquared.com/skin/article/view/1443